IMMUNOVATIVE THERAPIES
Immunovative Therapies is a biopharmaceutical company with financial support of the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. They specialize in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious disease.
IMMUNOVATIVE THERAPIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2004-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.immunovative.com
Total Employee:
51+
Status:
Active
Contact:
972-3-9702090
Email Addresses:
[email protected]
Total Funding:
16.5 M USD
Technology used in webpage:
SPF Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Incapsula
Current Advisors List
Current Employees Featured
Founder
Investors List
Trendlines Group
Trendlines Group investment in Venture Round - Immunovative Therapies
Misgav Technology Center
Misgav Technology Center investment in Venture Round - Immunovative Therapies
Malcolm Currie
Malcolm Currie investment in Seed Round - Immunovative Therapies
Office of the Chief Scientist
Office of the Chief Scientist investment in Seed Round - Immunovative Therapies
Trendlines Group
Trendlines Group investment in Seed Round - Immunovative Therapies
More informations about "Immunovative Therapies"
Immunovative Therapies - Crunchbase Company Profile & Funding
Organization. Immunovative Therapies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Immunovative Therapies is a …See details»
Organization | Immunovative Therapies - Purdue University
Organization Overview. First Clinical Trial. 2009 NCT00861107. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Immunovative Therapies, Ltd. Active Ingredients. …See details»
Novo Energies Corporation Announces the Appointment of …
Mar 19, 2012 FDA/CBER is the regulatory organization that reviews Immunovative's product submissions. Dr. Miller has been very influential in the development of policy in the cell and …See details»
Immunovative Therapies Ltd. - Drug pipelines, Patents, Clinical …
Explore Immunovative Therapies Ltd. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 4 news, and 6 literature, Disease Domain:Infectious Diseases, Technology …See details»
Immunovative Therapies - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Could an immunotherapy treatment from Israel cure …
Jan 29, 2019 According to the World Health Organization, almost half of all new liver cancer cases occur in China. ... Immunovative has 200 people currently enrolled in clinical trials. In 2019, the company will be looking to raise up to …See details»
Immunovative Therapies - Craft
Immunovative Therapies is a clinical stage biopharmaceutical company that develops immunotherapy products to treat cancer and infectious diseases. It is engaged in the …See details»
Immunovative Therapies - PitchBook
Immunovative Therapies was founded in 2004. Where is Immunovative Therapies headquartered? Immunovative Therapies is headquartered in Jerusalem, Israel. What is the size of Immunovative Therapies? Immunovative Therapies has 18 …See details»
Immunovative Therapies and Mirror Biologics Announce US FDA …
Jun 23, 2020 Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults The universal …See details»
Israel Ministry of Health Gives Clearance for Mirror …
Jan 30, 2023 Fingerut has dedicated over 16 years of her career with our predecessor company Immunovative Therapies and has been with Mirror Biologics, ... JLM-BioCity is a non-profit organization focused on developing …See details»
Mirror Biologics and Immunovative Therapies announce …
May 27, 2020 PHOENIX, AZ USA and Jerusalem, Israel (13/May/2020) - Mirror Biologics, Inc. (“MBI”), the commercial development arm of Israel-based Immunovative Therapies, Ltd. (“ITL”) …See details»
Immunovative, Inc. Announces Collaboration With the Robert H.
Oct 4, 2012 Immunovative, Inc. has today announced that Immunovative Therapies, Ltd. and the Robert H. Lurie Comprehensive Cancer Center at the Northwestern University Feinberg …See details»
CryoVax(R) : Next Generation Immunotherapy for Metastatic …
Nov 7, 2016 Immunovative Therapies, Ltd. (ITL) is an Israeli biopharmaceutical company specializing in the development, manufacture and testing of next generation of immunotherapy …See details»
Immunovative, Inc. Announces the Appointment of Members to …
Sep 4, 2012 The SAB serves as a Committee to the ITL Board of Directors and serves the joint interests of IMUN and ITL. Dr. Laurence Rulleau, PhD, a member of the IMUN Business …See details»
Individualised cancer vaccine - Immunovative Therapies
Immunovative Therapies is developing an individualised cancer vaccine candidate, known as AlloVax™. The vaccine candidate combines Immunovative's clinical ... If your organization has …See details»
The Max Foundation (Max) Expands Collaboration with Novartis to …
2 days ago The Max Foundation is a global health nonprofit organization dedicated to accelerating health equity. For 26 years, Max has pioneered practical, scalable, high-quality …See details»
WHO releases report on state of development of antibacterials
Jun 14, 2024 The World Health Organization (WHO) today released its latest report on antibacterial agents, including antibiotics, in clinical and preclinical development worldwide. …See details»
Immunovative Therapies and Mirror Biologics Announce US FDA …
Jun 23, 2020 Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults PRESS …See details»
Immunovative Therapies and Mirror Biologics Announce US FDA
Jun 23, 2020 The universal vaccine is designed to protect elderly adults from all respiratory viral infections, including COVID-19, influenza and any future mutations or novel viral outbreaks.See details»
International Pathogen Surveillance Network announces first …
Nov 26, 2024 The World Health Organization (WHO) and partners announced 10 projects that will receive almost US$ 2 million in grants to improve capacities in pathogen genomic …See details»